Fig. 7: Schematic model of the activated PKG I attenuates EGF-induced EGFR/MAPK/ERK signaling in ovarian cancer. | Cell Death & Disease

Fig. 7: Schematic model of the activated PKG I attenuates EGF-induced EGFR/MAPK/ERK signaling in ovarian cancer.

From: Increased endogenous PKG I activity attenuates EGF-induced proliferation and migration of epithelial ovarian cancer via the MAPK/ERK pathway

Fig. 7: Schematic model of the activated PKG I attenuates EGF-induced EGFR/MAPK/ERK signaling in ovarian cancer.The alternative text for this image may have been generated using AI.

By binding to EGFR, the activated PKG I inhibit the expression of the EGFR/MAPK/ERK pathway and thereby decreases the expression of nuclear phosphorylated ERK1/2, ultimately leading to suppressed cell growth and metastasis in human EOC.

Back to article page